NCT07047365 2026-02-02
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
Clinical Trials
7 trialsNCT06481956 2024-07-01
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
Zhejiang Cancer Hospital
Phase 2 Enrolling by invitation
NCT05901935 2023-06-13
DP303c in Patients With HER2-positive Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT05856383 2023-05-12
HER2-VIP
Zhejiang Cancer Hospital
Recruiting
NCT04903652 2022-04-07
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT04963608 2021-07-15
RWS of Inetetamab HER2 Positive Advanced Breast Cancer
Shandong Cancer Hospital and Institute
Unknown
NCT04185649 2019-12-04
The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Bio-Thera Solutions
Phase 3 Unknown